From: The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
Characteristics of patient cohort | Responders (n = 14) | IQR | Non-responders (n = 10) | IQR | p value |
---|---|---|---|---|---|
Female sex | 9 | Â | 3 | Â | 0.24 |
Median age, years | 41.0 | 35.0–46.0 | 40.0 | 32.0–44.0 | 0.4 |
Median age at diagnosis, years | 2.8 | 1.9–11.5 | 0.3 | 0.1–0.5 | 0.04 |
BMI (Kg/m2) | 21.6 | 20.9–22.7 | 21.9 | 18.9–24.8 | 0.8 |
Lung disease status | |||||
 Mild FEV1 (≥70%) | 1 |  | 1 |  |  |
 Moderate FEV1 (40–70%) | 7 |  | 3 |  |  |
 Severe FEV1 (≤40%) | 6 |  | 6 |  |  |
aMedian FEV1 (%) predicted at initiation | 46.0 | 33.0–57.0 | 38.5 | 33.0–50.0 | 0.4 |
aMedian FEV1 (%) predicted post-initiation | 45.0 | 35.0–57.0 | 33.5 | 30.0–48.0 | 0.2 |
Genotype | |||||
 ΔF508 homozyogous | 8 |  | 6 |  |  |
 ΔF508 heterozygous | 3 |  | 3 |  |  |
CF related co-morbidities | |||||
 Pancreatic insufficiency | 12 |  | 10 |  |  |
 CF-related diabetes | 4 |  | 4 |  |  |
 Impaired glucose tolerance | 5 |  | 3 |  |  |
 Liver disease | 1 |  | 1 |  |  |
 Bone disease | 5 |  | 3 |  |  |
 Sinus disease | 6 |  | 3 |  |  |
 Recurrent distal intestinal obstructive syndrome (DIOS) | 4 |  | 1 |  |  |
Cultured Pathogens | |||||
  P. aeruginosa | 14 |  | 10 |  |  |
  E. coli | 1 |  | 0 |  |  |
 Methicillin susceptible S. aureus | 0 |  | 3 |  |  |
 Group B streptococcus Spp. | 1 |  | 0 |  |  |